Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558624 | 0.91 | ALDH1A1 (0.55) | L3MBTL1ALDH1A1MAPTTSHRHPGD | |
| SCHEMBL743661 | 0.84 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1MAPTCYP1A2RAB9A | |
| SCHEMBL162735 | 0.84 | TSHR (0.50) | L3MBTL1ALDH1A1MAPTTSHRCYP1A2 | |
| SCHEMBL15842178 | 0.84 | ESR1 (0.54) | L3MBTL1ALDH1A1MAPTTSHRCYP1A2 | |
| SCHEMBL15956090 | 0.84 | TSHR (0.50) | L3MBTL1ALDH1A1MAPTTSHRCYP1A2 | |
| SCHEMBL23189019 | 0.84 | TSHR (0.50) | L3MBTL1ALDH1A1MAPTTSHRCYP1A2 | |
| SCHEMBL8408330 | 0.84 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1MAPTTSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL4217802 | 0.83 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1MAPTCYP1A2RAB9A | |
| SCHEMBL5700005 | 0.82 | SMN1; SMN2 (0.50) | L3MBTL1ALDH1A1MAPTTSHRCYP1A2 | |
| SCHEMBL5700217 | 0.82 | ESR1 (0.50) | L3MBTL1ALDH1A1MAPTTSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078933-B2 | Deuterated omega diphenylurea related compounds and intermediates | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2015-07-14 | — | — | US | disclosed |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) | 2015-06-25 | — | — | US | disclosed |
| US-8759531-B2 | Preparation method of fluoro-substituted deuterated diphenylurea | Suzhou Zelgen Biopharmaccceutical Co., Ltd. (CN) | 2014-06-24 | — | — | US | disclosed |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-8669369-B2 | Method and process for preparation and production of deuterated Ω-diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-03-11 | — | — | US | disclosed |
| US-20130060043-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD (CN) | 2013-03-07 | — | — | US | disclosed |
| US-20130035492-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. | 2013-02-07 | — | — | US | disclosed |
| WO-2011113367-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED Ω-DIPHENYLUREA | 苏州泽璟生物制药有限公司 (CN) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113368-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | 苏州泽璟生物制药有限公司 (CN) | 2011-09-22 | — | — | WO | disclosed |
| CN-100515419-C | Substituted benzazoles and its application as inhibitors of Raf kinase | CHIRON CORP (US) | 2009-07-22 | — | — | CN | disclosed |
| EP-1270582-B1 | TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES | MITSUBISHI RAYON CO (JP) | 2006-08-30 | — | — | EP | disclosed |
| CN-1655779-A | substituted indoles and their use as Raf kinase inhibitors | CHIRON CORP (US) | 2005-08-17 | — | — | CN | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | L3MBTL1 3393/4885ALDH1A1 3993/4885MAPT 4407/4885 |
| US-20130060043-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | CCND3, UBE2D3, VDR | L3MBTL1 2415/4885ALDH1A1 3553/4885MAPT 4194/4885 |
| US-20130035492-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | PNLIP, PDXK, PNP | L3MBTL1 3368/4885ALDH1A1 2645/4885MAPT 4536/4885 |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | PNLIP, PDXK, DGKK | L3MBTL1 2339/4885ALDH1A1 2354/4885MAPT 4529/4885 |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | CCND3, UBE2D3, VDR | L3MBTL1 2415/4885ALDH1A1 3553/4885MAPT 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.